UNSPSC 51162625: Droxypropine

This classification denotes an antitussive agent and analgesic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 94J1SMK20X. European Medicines Agency schedules Droxypropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06422MIG. Droxypropine generally arises in the molecular formula C18H27NO3.

UNSPSC 51162625 Droxypropine, a Commodity code, covers pharmaceutical products that state and local governments procure for community health, emergency response, and public health initiatives. Recent solicitations show purchasing of naloxone (opioid overdose reversal), generic multi-source pharmaceuticals, and over-the-counter products through both direct county procurement and cooperative purchasing vehicles. The issuing bodies include county health departments (Seminole County, Florida) and state-level cooperative purchasing alliances administering multi-jurisdictional pharmaceutical supply agreements (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Vendors must comply with Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), and FDA requirements, and must maintain specified insurance including commercial general liability and professional liability coverage. Contracts typically carry two-year initial terms with renewal or extension options.

Geographic activity centers on Florida and Minnesota, with MMCAP's multi-state cooperative structure extending reach across participating jurisdictions including Oregon. Seminole County issued IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, response due July 26, 2026 (as posted, though a noted deadline discrepancy in the source suggests verification is warranted). The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Price competitiveness weighs heavily in MMCAP evaluation (75 percent) alongside cGMP and DSCSA compliance. Vendors should expect administrative fees, performance penalties for late reporting or missed onboarding, and the requirement to maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place.